Change in glucose-lowering medication regimens in individuals with type 2 diabetes mellitus during the COVID-19 pandemic in Germany.

Louis JacobSarah RickwoodWolfgang RathmannKarel Kostev

Published in: Diabetes, obesity & metabolism (2021)

The coronavirus disease-2019 (COVID-2019) pandemic had a strong impact on glucose-lowering drug use in T2DM patients in Germany. More research is warranted to further investigate the treatment and management of T2DM individuals during the COVID-19 era in Germany and elsewhere.

Keyphrases

coronavirus disease
end stage renal disease
ejection fraction
newly diagnosed
sars cov
chronic kidney disease
healthcare
blood glucose
prognostic factors
blood pressure
respiratory syndrome coronavirus
type diabetes
patient reported outcomes
skeletal muscle
peritoneal dialysis